STARmed to Accelerate Global Market Entry of EUSRA & ELRA Products Through Olympus

STARmed Expansion

STARmed, a leading developer and manufacturer of medical devices for tumor ablation, today announced global market expansion of its EUSRA and ELRA products, through Olympus, a global MedTech company based in Japan.

EUSRA and ELRA Products

EUSRA and ELRA products had been distributed by Taewoong Medical Co., Ltd., a Korean manufacturer of gastrointestinal medical devices. With the completion of Olympus’ acquisition of Taewoong Medical, Olympus has become a global distribution partner of STARmed’s EUSRA and ELSA products. This will enable STARmed to accelerate its global market expansion and provide better healthcare to patients around the world.

“Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy,” said Henry Shin, CEO of STARmed. “We look forward to our products being made available to more patients through Olympus’ global distribution network.”

“We recognize STARmed’s EUSRA and ELRA products as well-received and high-quality products,” said Mike Callaghan, Vice President, General Manager of GI EndoTherapy at Olympus. “Moving forward, we will further strengthen our position in this market, strive to elevate the standard of care, and in turn, offer new hope to patients and healthcare providers around the world.”

SourceSTARmed

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”